4//SEC Filing
DiBiase Mary 4
Accession 0001628280-23-036757
CIK 0001501697other
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 4:40 PM ET
Size
5.5 KB
Accession
0001628280-23-036757
Insider Transaction Report
Form 4
DiBiase Mary
Chief Operating Officer
Transactions
- Sale
Common Stock
2023-11-01$0.73/sh−67,695$49,417→ 310,844 total
Footnotes (3)
- [F1]These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023.
- [F2]Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6839 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001880179
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 8:00 PM ET
- Accepted
- Nov 3, 4:40 PM ET
- Size
- 5.5 KB